258
Participants
Start Date
December 29, 2021
Primary Completion Date
January 4, 2024
Study Completion Date
January 4, 2024
Nemolizumab
Participants received a loading dose of 60 mg nemolizumab at Baseline followed by 2 Subcutaneous (SC) injections for a total dose of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Nemolizumab
Participants received 2 SC injections of 30 mg nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Placebo
Participants received 2 SC injections of 30 mg placebo-matched to nemolizumab once every 4 weeks i.e. at Week 4 and Week 8.
Galderma Investigational Site 6301, Budapest
Galderma Investigational Site 6305, Miskolc
Galderma Investigational Site 6304, Kecskemét
Galderma Investigational Site 6310, Szentes
Galderma Investigational Site 6298, Szombathely
Galderma Investigational Site 9995, The Bronx
Galderma Investigational Site 9998, Great Neck
Galderma Investigational Site 7038, Fresh Meadows
Galderma Investigational Site 6292, Córdoba
Galderma Investigational Site 9968, Norfolk
Galderma Investigational Site 7007, Winston-Salem
Galderma Investigational Site 5171, Madrid
Galderma Investigational Site 6190, Madrid
Galderma Investigational Site 6309, Alcobendas
Galderma Investigational Site 9999, Spartanburg
Galderma Investigational Site 7027, Columbus
Galderma Investigational Site 7032, Sanford
Galderma Investigational Site 7026, Hollywood
Galderma Investigational Site 9965, Miami
Galderma Investigational Site 7037, Coral Gables
Galderma Investigational Site7016, Miami
Galderma Investigational Site 9970, Boca Raton
Galderma Investigational Site 7004, Tampa
Galderma Investigational Site 7025, Tampa
Galderma Investigational Site 9967, Chattanooga
Galderma Investigational Site 6295, Seville
Galderma Investigational Site 6311, Valencia
Galderma Investigational Site 6278, Manises
Galderma Investigational Site 9963, Roseville
Galderma Investigational Site 9969, Wauwatosa
Galderma Investigational Site 9982, Minneapolis
Galderma Investigational Site 7020, Edina
Galderma Investigational Site 7035, Kansas City
Galderma Investigational Site 9983, Overland Park
Galderma Investigational Site 9972, Wichita
Galderma Investigational Site 7022, McKinney
Galderma Investigational Site 7040, Dallas
Galderma Investigational Site 9977, Greenville
Galderma Investigational Site 7039, Arlington
Galderma Investigational Site 7011, Houston
Galderma Investigational Site 7019, The Woodlands
Galderma Investigational Site 7010, San Antonio
Galderma Investigational Site 9966, El Paso
Galderma Investigational Site 9971, Denver
Galderma Investigational Site 9962, Las Vegas
Galderma Investigational Site 9996, Los Angeles
Galderma Investigational Site 9978, Lynwood
Galderma Investigational Site 7003, Whittier
Galderma Investigational Site 7015, La Palma
Galderma Investigational Site 9991, Glendale
Galderma Investigational Site 7018, Glendale
Galderma Investigational Site 9973, Tarzana
Galderma Investigational Site 7028, Victorville
Galderma Investigational Site 7017, Riverside
Galderma Investigational Site 9989, Bakersfield
Galderma Investigational Site 9992, Roseburg
Galderma Investigational Site 9964, Victorville
Galderma Investigational Site 9988, Bloomfield
Galderma Investigational Site 9980, Middlebury
Galderma Investigational Site 6294, Brodnica
Galderma Investigational Site 6296, Lodz
Galderma Investigational Site 6293, Olkusz
Galderma Investigational Site 6297, Wroclaw
Galderma Investigational Site 5580, L'Hospitalet de Llobregat
Lead Sponsor
Galderma R&D
INDUSTRY